StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.21−0.07 (-0.21%)

Close on Nov 17, 2026Market cap $6.86BP/E –Yield –

Immunovant market cap

Market capitalization is the share price multiplied by the number of shares outstanding.

Immunovant's market cap was $7.64B on Nov 11, 2026, against $4.21B a year earlier. Over the last 5 years it ranged from $454.28M to $8.42B, with a median of $3.63B.

Market Cap at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$7.64B+72.2%
2025Dec 31, 2025$4.44B+22.2%
2024Dec 31, 2024$3.63B-34.4%
2023Dec 29, 2023$5.54B+167.5%
2022Dec 30, 2022$2.07B+111.3%
2021Dec 31, 2021$979.79M-78.3%
2020Dec 31, 2020$4.52B+2319.6%
2019Dec 31, 2019$186.87M–

More Immunovant figures

See a number that looks wrong?